Kinase Fusion-Related Thyroid Carcinomas: Towards Predictive Models for Advanced Actionable Diagnostics

Area of Science:

• Oncology
• Molecular Biology
• Pathology

Background:

• Thyroid cancer treatment has advanced with targeted therapies, particularly kinase inhibitors.
• Kinase fusions are found in 10-15% of thyroid cancers, representing a significant subset for targeted therapy.
• Molecular testing platforms are now integrated into clinical practice for identifying targetable tumors.

Purpose of the Study:

• To review the clinicopathologic and molecular features of kinase fusion-driven thyroid carcinoma (KFTC).
• To summarize current literature on KFTC, including investigational progress and challenges.
• To highlight the need for standardized, evidence-based treatment regimens for KFTC.

Main Methods:

• Review of current literature on KFTC.
• Analysis of clinicopathologic and molecular features.
• Examination of molecular predictors of kinase inhibitor resistance.

Main Results:

• Selective kinase inhibitors are a successful targeted therapy for a subset of thyroid carcinomas.
• An integrative approach combining traditional pathology and molecular assays is essential for diagnosis and treatment.
• Research is ongoing to characterize KFTC and identify resistance mechanisms.

Conclusions:

• Kinase fusion-driven thyroid carcinoma (KFTC) represents a unique and important subset of thyroid neoplasms.
• Further research is needed to establish standardized treatment regimens and overcome challenges in managing KFTC.
• Understanding molecular predictors of resistance is key to optimizing kinase inhibitor therapy.